2024/07/16 17:35:46 | |
---|---|
Price | |
3.46 EUR | |
Difference | 0.35% (0.01) |
ISIN | FR0004056851 |
Symbol | VLA |
Exchange | Xetra |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 959 EUR |
Benchmark | CAC 40 INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 3.398 EUR |
High | 3.53 EUR |
Low | 3.398 EUR |
Close (prev. day) | 3.448 EUR |
VWAP | 3.493 EUR |
Volume (pcs) | 11,430 |
Trading volume | 39,924.95 |
Number of trades | 28 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/07/12 |
![]() |
Global Equity Ratings |
![]() |
2024/06/21 |
![]() |
Global Equity Ratings |
![]() |
2024/06/14 |
![]() |
Global Equity Ratings |
![]() |
2024/05/29 |
![]() |
Global Equity Ratings |
![]() |
2024/04/26 |
![]() |
Global Equity Ratings |
![]() |
2024/07/16 17:35:46 | |
---|---|
Price | |
3.46 EUR | |
Difference | 0.35% (0.01) |
ISIN | FR0004056851 |
Symbol | VLA |
Exchange | Xetra |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 959 EUR |
Benchmark | CAC 40 INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 3.398 EUR |
High | 3.53 EUR |
Low | 3.398 EUR |
Close (prev. day) | 3.448 EUR |
VWAP | 3.493 EUR |
Volume (pcs) | 11,430 |
Trading volume | 39,924.95 |
Number of trades | 28 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -18.66% | -51.54% | - |
Perf (abs.) | -0.79 | -3.68 | - |
Beta | 1.42 | 1.30 | 1.06 |
Volatility | 55.97 | 51.48 | - |
Ø price 5 days | Ø volume 5 days (pcs.) | 3.39 EUR (6,364) |
Ø price 30 days | Ø volume 30 days (pcs.) | 3.41 EUR (9,203) |
Ø price 100 days | Ø volume 100 days (pcs.) | 3.54 EUR (9,794) |
Ø price 250 days | Ø volume 250 days (pcs.) | 4.60 EUR (9,016) |
YTD High | date | 4.97 EUR (2024/01/09) |
YTD Low | date | 2.99 EUR (2024/03/06) |
52 Weeks High | date | 7.03 EUR (2023/11/10) |
52 Weeks Low | date | 2.99 EUR (2024/03/06) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/07/16 | 17:35 | 3.46 EUR | 0.04 | 28 |
Vienna Stock Exchange | 2024/07/16 | 15:30 | 3.434 EUR | 0.00 | 4 |
Tradegate | 2024/07/16 | 19:36 | 3.45 EUR | 0.16 | 66 |
Stuttgart | 2024/07/16 | 16:52 | 3.542 EUR | 0.02 | 6 |
Munich | 2024/07/16 | 19:33 | 3.494 EUR | 0.01 | 4 |
London Stock Exchange | 2024/05/02 | 17:57 | 3.40 EUR | 0.03 | 1 |
Hanover | 2024/07/16 | 08:48 | 3.396 EUR | 0.00 | 1 |
Hamburg | 2024/07/16 | 08:21 | 3.382 EUR | 0.00 | 1 |
Frankfurt | 2024/07/16 | 19:13 | 3.484 EUR | 0.02 | 7 |
FINRA other OTC Issues | 2024/07/12 | 16:44 | 3.70 USD | 0.00 | 1 |
Euronext Paris | 2024/07/16 | 17:35 | 3.494 EUR | 1.48 | 813 |
Euronext Milan MTF Trading After Hours | - | - | - | 0.00 | - |
Duesseldorf | 2024/07/16 | 20:02 | 3.488 EUR | 0.00 | 6 |
Berlin | 2024/07/16 | 08:08 | 3.372 EUR | 0.00 | 1 |
VALNEVA SE |
- - |
Campus Bio-Ouest, 6, rue Alain Bombard - 44800 Saint-Herblain |
Telefon: +33-2-28-07-37-10 |
Fax: + |
E-mail: info@valneva.com |
Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France. |
Thomas Lingelbach | Chairman of Managing Board |
Dipal Patel | Member of Executive Committee |
Franck Grimaud | Member of Executive Committee |
Frederic Jacotot | Member of Executive Committee |
Juan Carlos Jaramillo | Member of Executive Committee |
Peter Bühler | Member of Executive Committee |
Petra Pesendorfer | Member of Executive Committee |
Vincent Dequenne | Member of Executive Committee |
Anne-Marie Graffin | Chairman of Supervisory Board |
Kathrin Jansen | Member of Supervisory Board |
Danièle Guyot-Caparros | Member of Supervisory Board |
James Connolly | Member of Supervisory Board |
James Sulat | Member of Supervisory Board |
Maïlys Ferrère | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer